| Literature DB >> 35270227 |
Remedios López-Liria1, María Ángeles Valverde-Martínez1, Antonio López-Villegas2, Rafael Jesús Bautista-Mesa3, Francisco Antonio Vega-Ramírez4, Salvador Peiró5, Cesar Leal-Costa6.
Abstract
(1) Background: The aim of this systematic review was to compare the cost-effectiveness of two follow-up methods (face-to-face and telemedicine) used in dermatology in the last ten years. (2)Entities:
Keywords: cost–benefit analysis; follow-up studies; health-related quality of life; pacemakers; teledermatology; telemedicine
Mesh:
Year: 2022 PMID: 35270227 PMCID: PMC8909884 DOI: 10.3390/ijerph19052534
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Databases and search terms.
| Databases and Search Terms | Results | Selected Articles |
|---|---|---|
| SCOPUS, SCIELO, MEDLINE “Cos-Benefit Analysis” AND “Dermatology” AND “Telemedicine” “Cost-Utility Analysis” AND “Dermatology” AND “Telemedicine” “Economic Evaluation” AND “Dermatology” AND “Telemedicine” “Cost-Effectiveness Analysis” AND “Dermatology” AND “Telemedicine” “Cost- Benefit Analysis” AND “Dermatology” AND “Primary Health Care” “Teledermatology” AND “Remote Consult * AND “Conventional” OR "Face-to-face" OR “Standard” OR “In-person” AND Cost * “Telederm*” AND “Telemed *” AND “Dermatol *” AND “Skin Disease” AND “Telehealth” AND “Dermatol *” AND “Conventional” OR “Standard” OR “Face-to-face” OR “In-Person” OR “Primary Health Care” OR “Remote Consult*” AND “Cost *” AND “Cost-Benefit Analysis” AND “Cost-Utility Analysis” AND “Economic Evaluation” AND “Cost-Effectiveness Analysis” | 100 | 26 |
| PUBMED “Cos-Benefit Analysis” AND “Dermatology” AND “Telemedicine” “Cost-Utility Analysis” AND “Dermatology” AND “Telemedicine” “Economic Evaluation” AND “Dermatology” AND “Telemedicine” “Cost-Effectiveness Analysis” AND “Dermatology” AND “Telemedicine” “Cost- Benefit Analysis” AND “Dermatology” AND “Primary Health Care” “Teledermatology” AND “Remote Consult * AND “Conventional” OR "Face-to-face" OR “Standard” OR “In-Person” AND “Cost * “Telederm *” AND “Telemed *” AND “Dermatol *” AND “Skin Disease” AND “Telehealth” AND “Dermatol *” AND “Conventional” OR “Standard” OR “Face-to-face” OR “In-Person” OR “Primary Health Care” OR “Remote Consult*” AND “Cost *” AND “Cost-Benefit Analysis” AND “Cost-Utility Analysis” AND “Economic Evaluation” AND “Cost-Effectiveness Analysis” | 16 | 1 |
“*” = Truncation.
Figure 1Flowchart of articles selection process. n = number of articles.
Description of the main results in the selected articles.
| Author, Year | Type of Study | Dermatology | Main Results |
|---|---|---|---|
| Zakaria, 2020 [ | A retrospective cost-minimization analysis 1297 patients did not require in-person consultation 801 patients required in-person consultation 646 patients did not require dermatological consultation 1452 had consultation and follow-up | Compared dermatology | Average cost/patient TD: $559.84 |
| López-Villegas, 2020 [ | Inter-level multicentre retrospective study 2629 patients required in-person consultation 4349 patients diagnosed with TD | Teledermatology units compared to conventional monitoring at hospitals | Savings of 61.86% of hospital visits |
| Vidal-Alaball, 2018 [ | Observational Study | A cost–savings analysis comparing teledermatology with traditional dermatology consultations (face-to-face) | TD saved 4502 in-person visits. |
| Yang, 2018 [ | A retrospective study of the cases | Analysis compared the cost of each patient case with use of the TD consultation model vs. conventional care | Compared with conventional care, TD had an average expected cost savings of $10.00 to $52.65 per TD consultation |
| Zarca, 2018 [ | Retrospective cohort study | Evaluate the effectiveness and costs of tele-expertise in dermatology | For 368 patients every year, the average cost is €184 for completed treatment plans distributed as follows: 34% investment, 66% operating cost (30% human resource, 36% software) |
| Datta, 2015 [ | Randomized clinical trial | To assess the costs and utility of a store-and-forward teledermatology referral process compared with conventional referral process. | The TD cost per patient was $30 lower and, from a societal perspective, saved $82 |
| Os-Medendorp, 2012 [ | Randomized controlled study with economic evaluation | Determine the cost-effectiveness of individualized e-health compared with usual face-to-face care | Both interventions proved effective regarding quality of life and severity of illness, but there were no significant differences. |
| Parsi, 2011 [ | Randomized Controlled Trial | Compare cost-effectiveness of conventional in-office care with a patient-centered, | Both improved patient quality of life and proved effective: patients gained 23.3 weeks of quality of life with TD and 24.1 with in-person care |
Description of “Cost and Effectiveness” Variables.
| Author, Year | Direct Costs | Indirect Costs | Exclusion of Costs | Effectiveness Variables |
|---|---|---|---|---|
| Zakaria, 2020 [ | Costs associated with | No reference made to indirect costs | Exclusion of rent costs, clinical supplies, public services and social costs | Does not include effectiveness |
| López-Villegas, 2020 [ | Costs from PHS perspective: | Patient Cost Perspective: | Exclusion of structural costs (electricity, telecommunications, construction and maintenance) | Effectiveness was not measured |
| Vidal-Alaball, 2018 [ | Number of PC, dermatological and TD visits. | Costs included building maintenance, IT services, gas, electricity, telephone–internet connections | Exclusion of costs incurred by companions, loss of free time, technical and maintenance costs, training costs for professionals and medical insurance | Effectiveness was not measured |
| Yang, 2018 [ | Direct medical | Indirect costs | Separate | PC doctors were asked about their satisfaction with using TD |
| Zarca, 2018 [ | Evaluates image quality but not diagnostic precision | The proportion of patients with a completed treatment plan for skin lesions, the proportion of technical problems, the quality of the pictures, the investment and operating costs and the satisfaction of the professionals | They could not evaluate the diagnostic accuracy of telemedicine; the causes of “failed upload, unanswered requests | Satisfaction survey for doctors. |
| Datta, 2015 [ | The cost elements from the VA perspective included: TD intervention or referral; referral and follow-up visits to the dermatology clinic; dermatological medications prescribed; travel cost reimbursement to patients paid by the VA; and dermatology-related hospitalizations | Dermatological care | They did not include the equipment | Time trade-off determines the quality of life one experiences in a given state of health by assessing the equivalence point between living a longer life with the given medical condition vs. a shorter life in perfect health |
| Os-Medendorp, 2012 [ | Costs of primary care, e-health service and outpatient clinics | Two modules online of the ‘Health and Labour Questionnaire’ | Equipment costs not included | Quality of life, itch intensity and severity of atopic dermatitis |
| Parsi, 2011 [ | Social perspective: | Costs of patient’s time: patient wages/minute, duration of visit, cost of patient’s time/visit | Not included | Quality-adjusted life expectancy |
PC = Primary care; TD: Teledermatology; DLQI = Dermatology Life Quality Index; IDQOL = Infants’ Dermatitis Quality of Life Index; VAS = Visual Analogue Scale; HLQOL = Quality of life measured by the current health condition of an individual; QALY = Quality-adjusted life years; QALE = Quality-adjusted life expectancy; EQ-5D = European Quality of Life 5-Dimension Questionnaire.
Methodological Quality of Studies.
| Study Quality | External Validity | Study Bias | Confounding and Selection Bias | Study | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author (Year) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | Total | Quality |
| Zakaria, 2020 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 23 | Good |
| López-Villegas, 2020 [ | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 21 | Good |
| Vidal-Alaball, 2018 [ | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 17 | Fair |
| Yang, 2018 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 22 | Good |
| Zarca, 2018 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 21 | Good |
| Datta, 2015 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 25 | Good |
| Os-Medendorp, 2012 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 25 | Good |
| Parsi, 2011 [ | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 22 | Good |